Spyre Therapeutics, Inc.SYREEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing targeted next-generation therapies for patients with rare, serious autoimmune and inflammatory diseases. It advances pipeline candidates through preclinical and early clinical stages to address unmet medical needs for global patient populations.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| FMR LLC | 15.00% | 7.6M | ▲ +2.04pp | 2024-11-12 |
| Fairmount Funds Management LLC | 9.99% | 4.0M | — | 2024-04-25 |
| Peter E. Deutsch | 6.99% | 3.6M | — | 2024-10-23 |
| Perceptive Advisors LLC | 5.70% | 2.9M | ▼ -1.50pp | 2024-11-14 |
| Venrock Healthcare Capital Partners III, L.P. | 5.30% | 2.7M | ▼ -4.69pp | 2024-11-14 |
| BlackRock, Inc. | 5.20% | 2.7M | flat | 2024-11-08 |
| Commodore | 3.90% | 2.0M | ▼ -1.50pp | 2024-11-14 |
| EcoR1 Capital, LLC | 2.50% | 887.1K | — | 2024-02-14 |
| Deep Track Capital, LP | 1.97% | 1.0M | — | 2024-11-14 |
| Avoro Capital Advisors LLC | 1.70% | 885.1K | ▼ -3.40pp | 2024-11-14 |
| Logos Global Management LP | 0.40% | 150.0K | — | 2024-02-14 |
| Nantahala Capital Management, LLC | 0.00% | 773 | — | 2024-02-14 |
| Baker Bros. Advisors LP | 0.00% | 773 | — | 2024-02-14 |
Insider Transactions
Net 90d: −$9.81M · buys $0 / sells $9.81MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-05-01 | Cameron Turtle | Chief Executive Officer | Sell (open market) | 5.3K | $69.54 | $368.6K |
| 2026-05-01 | Cameron Turtle | Chief Executive Officer | Sell (open market) | 3.6K | $70.77 | $254.8K |
| 2026-05-01 | Cameron Turtle | Chief Executive Officer | Sell (open market) | 1.0K | $71.76 | $71.8K |
| 2026-05-01 | Cameron Turtle | Chief Executive Officer | Sell (open market) | 3.1K | $73.14 | $226.7K |
| 2026-05-01 | Cameron Turtle | Chief Executive Officer | Sell (open market) | 1.7K | $74.23 | $126.2K |
| 2026-05-01 | Cameron Turtle | Chief Executive Officer | Sell (open market) | 300 | $74.96 | $22.5K |
| 2026-05-01 | Burrows Scott L | Chief Financial Officer | Option exercise | 12.5K | $14.50 | $181.3K |
| 2026-05-01 | Burrows Scott L | Chief Financial Officer | Sell (open market) | 12.5K | $71.37 | $892.1K |
| 2026-05-01 | Sheldon Sloan | Chief Medical Officer | Option exercise | 78.3K | $27.46 | $2.15M |
| 2026-05-01 | Sheldon Sloan | Chief Medical Officer | Sell (open market) | 21.3K | $69.53 | $1.48M |
1–10 of 28
Page 1 / 3